NanoViricides, Inc. (NYSE American: NNVC) has entered into a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.
The company, a clinical-stage pioneer in broad-spectrum antivirals based on host-mimetic nanomedicine technology, is advancing its lead drug candidate NV-387. This drug has received Orphan Drug Designation from the U.S. FDA, potentially offering seven years of market exclusivity, tax credits, and fee exemptions upon approval. NV-387 is designed as a first-visit treatment for respiratory viral illnesses and has shown efficacy in lethal animal models of influenza, RSV, coronaviruses, monkeypox, smallpox, and measles.
This capital raise underscores investor confidence in NanoViricides' platform and its potential to address unmet medical needs in antiviral therapy. The funds will likely support ongoing clinical trials and manufacturing scale-up. For more details, the full press release is available at https://ibn.fm/Z8Etj.
NanoViricides is traded on NYSE American under the ticker NNVC. The company's newsroom provides updates at https://ibn.fm/NNVC. This offering represents a strategic move to bolster its financial position as it advances its antiviral pipeline.
